跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
MINT-APREMILAST - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
MINT-APREMILAST
Authorized
STANDARD
MINT-APREMILAST
mint pharmaceuticals inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
d92ef5a328f7458b
Company
mint pharmaceuticals inc
Type
Standard
Approval Details
Approval Id
d92ef5a328f7458b
Drug Approval Canada Name
MINT-APREMILAST
Product Name
MINT-APREMILAST
Status
Marketed
Status Date
2023-01-06
Original Market Date
2023-01-06
Din
02525747
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
90:24.24.92
Atc Original
L04AA32 APREMILAST
Atc Name
l 04 aa 32
Aig Number
0156231002
Company Name
mint pharmaceuticals inc
Company Address
6575 Davand Drive, Mississauga, Ontario, Canada, L5T 2M3
Active Ingredients
APREMILAST
30 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
d92ef5a328f7458b
Type
Standard
Back to Health Canada Approvals